8-bromodibenzo[b,d]furan-2-sulfonic acid | 792888-22-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 8-bromodibenzo[b,d]furan-2-sulfonic acid
• 英文别名: 8-Bromo-2-dibenzofuransulfonic acid；8-bromodibenzofuran-2-sulfonic acid
• CAS: 792888-22-3
• 化学式: C₁₂H₇BrO₄S
• 分子量: 327.155
• InChiKey: IQOLCHKEYNGSGI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  8-bromodibenzo[b,d]furan-2-sulfonic acid 在 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以80%的产率得到8-bromodibenzo[b,d]furan-2-sulfonyl chloride
  参考文献：
  名称：

  A Selective Matrix Metalloprotease 12 Inhibitor for Potential Treatment of Chronic Obstructive Pulmonary Disease (COPD): Discovery of (S)-2-(8-(Methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3-methylbutanoic acid (MMP408)

  摘要：

  Matrix metalloprotease 12 plays a significant role in airway inflammation and remodeling. Increased expression and production of MMP-12 have-been found in the lung of human COPD patients. MMP408 (14), a potent and selective MMP-12 inhibitor, was derived from a potent matrix metalloprotease 2 and 13 inhibitor via lead optimization and has good physical properties and bioavailability. The compound blocks rhMMP-12-induced lung inflammation in a mouse model and was advanced for further development for the treatment of COPD.

  DOI：

  10.1021/jm900093d
• 作为产物：
  描述：

  2-溴二苯并呋喃 在 氯磺酸 作用下， 以 二氯甲烷 为溶剂， 以63%的产率得到8-bromodibenzo[b,d]furan-2-sulfonic acid
  参考文献：
  名称：

  A Selective Matrix Metalloprotease 12 Inhibitor for Potential Treatment of Chronic Obstructive Pulmonary Disease (COPD): Discovery of (S)-2-(8-(Methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3-methylbutanoic acid (MMP408)

  摘要：

  Matrix metalloprotease 12 plays a significant role in airway inflammation and remodeling. Increased expression and production of MMP-12 have-been found in the lung of human COPD patients. MMP408 (14), a potent and selective MMP-12 inhibitor, was derived from a potent matrix metalloprotease 2 and 13 inhibitor via lead optimization and has good physical properties and bioavailability. The compound blocks rhMMP-12-induced lung inflammation in a mouse model and was advanced for further development for the treatment of COPD.

  DOI：

  10.1021/jm900093d

文献信息

• Methods and apparatus for accelerated orthokeratology
  申请人：——

  公开号：US20010016731A1

  公开（公告）日：2001-08-23

  An accelerated method of orthokeratology includes the steps of softening of the cornea with a softening agent, applying a mold to reshape the cornea to a desired anterior curvature, and rapidly restabilizing or “fixing” the corneal tissues so that the cornea retains its new configuration. A chemical softening agent, such as glutaric anhydride is applied to the cornea to soften the cornea, after which a specially designed mold of predetermined curvature and configuration is applied to the cornea. Slight downward pressure is applied to the mold for a predetermined period of time to re-shape the cornea. The mold is maintained in position while a stabilizing agent, such as a UV light source, is positioned above the mold. The stabilizing agent, i.e. UV light, is applied to the cornea for a predetermined time, wherein the stabilizing agent immediately restabilizes the corneal tissue so that the cornea immediately retains its shape upon removal of the mold. The stabilization process can also be used for patients having already undergone traditional orthokeratology to eliminate the need to continue wearing a retainer to maintain the shape of the cornea.

  角膜矫形术的加速方法包括以下步骤：用软化剂软化角膜，使用模具将角膜重塑成所需的前弧度，并迅速重新稳定或 "固定 "角膜组织，使角膜保持新的形态。在角膜上涂抹化学软化剂（如戊二酸酐）以软化角膜，然后在角膜上涂抹专门设计的具有预定弧度和结构的模具。在预定时间内对模具施加轻微的向下压力，以重新塑形角膜。将稳定剂（如紫外线光源）置于模具上方时，模具将保持在原位。将稳定剂（即紫外线）照射到角膜上，持续预定的时间，其中稳定剂会立即重新稳定角膜组织，使角膜在移除模具后立即保持其形状。稳定过程也可用于已接受传统角膜矫形术的患者，使其无需继续佩戴保持器来保持角膜的形状。
• [EN] DIBENZOFURAN DERIVATIVE CATHEPSIN K INHIBITOR, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF<br/>[FR] INHIBITEUR DE LA CATHEPSINE K DÉRIVÉ DU DIBENZOFURANE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION MÉDICALE<br/>[ZH] 一种二苯并呋喃类衍生物组织蛋白酶K抑制剂及其制备方法和医药用途
  申请人：SHENZHEN SALUBRIS PHARM CO LTD

  公开号：WO2021147882A1

  公开（公告）日：2021-07-29

  提供了一系列的组织蛋白酶K的抑制剂，尤其提供了一种二苯并呋喃衍生物组织蛋白酶K的抑制剂，属于化学药物技术领域。还涉及包含这些化合物的药物组合物以及使用该化合物治疗骨关节炎等疾病的药物中的用途。
• METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY
  申请人：Ista Pharmaceuticals, Inc.

  公开号：EP1051655A1

  公开（公告）日：2000-11-15
• EP1051655A4
  申请人：——

  公开号：EP1051655A4

  公开（公告）日：2003-03-19
• US6161544A
  申请人：——

  公开号：US6161544A

  公开（公告）日：2000-12-19